trovafloxacin has been researched along with Adverse Drug Event in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ding, D; Fang, H; Kelly, R; Liu, Z; Shi, Q; Tong, W | 1 |
| Kang, MG; Park, D; Park, T; Yang, H | 1 |
| Graf, K; Kaden, T; Li, R; Mosig, AS; Raasch, M; Rennert, K | 1 |
| Crogan-Grundy, C; Funk, J; Nguyen, DG; Presnell, SC; Robbins, JB; Roth, AB; Singer, T | 1 |
| Boada, C; Boada, JN; Fernández, E; García, M; García-Sáiz, M; Gómez, E | 1 |
| Ganey, PE; Roth, RA; Shaw, PJ | 1 |
1 review(s) available for trovafloxacin and Adverse Drug Event
| Article | Year |
|---|---|
Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity.
Topics: Animals; Anti-Infective Agents; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Drug-Related Side Effects and Adverse Reactions; Fluoroquinolones; Humans; Inflammation; Naphthyridines; Stress, Physiological | 2010 |
6 other study(ies) available for trovafloxacin and Adverse Drug Event
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Models, Biological; Predictive Value of Tests | 2011 |
Trovafloxacin drives inflammation-associated drug-induced adverse hepatic reaction by changing macrophage polarization.
Topics: Chemical and Drug Induced Liver Injury; Drug-Related Side Effects and Adverse Reactions; Fluoroquinolones; Humans; Inflammation; Liver; Macrophages; Naphthyridines | 2022 |
Evaluation of drug-induced liver toxicity of trovafloxacin and levofloxacin in a human microphysiological liver model.
Topics: Animals; Cytokines; Drug-Related Side Effects and Adverse Reactions; Endothelial Cells; Fluoroquinolones; Hepatitis; Humans; Levofloxacin | 2023 |
Bioprinted 3D Primary Liver Tissues Allow Assessment of Organ-Level Response to Clinical Drug Induced Toxicity In Vitro.
Topics: Albumins; Bioprinting; Cell Culture Techniques; Cell Proliferation; Cells, Cultured; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP3A; Drug-Related Side Effects and Adverse Reactions; Fluoroquinolones; Hepatocytes; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Levofloxacin; Lipopolysaccharides; Liver; Naphthyridines; Platelet Endothelial Cell Adhesion Molecule-1 | 2016 |
Net efficacy adjusted for risk (NEAR): a simple procedure for measuring risk:benefit balance.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Cardiovascular Diseases; Drug-Related Side Effects and Adverse Reactions; Fluoroquinolones; Gemifloxacin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Models, Theoretical; Naphthyridines; Pneumonia; Preventive Medicine; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome | 2008 |